FDA Approves New Treatment for Chemotherapy-Induced Nausea

Thursday, September 10, 2015 - 00:31

The US Food and Drug Administration (FDA) has approved Varubi (Rolapitant) – a drug to prevent chemotherapy-induced nausea and vomiting, which are the most common side effects of cancer chemotherapy and radiation therapy.

 The headquarters of the U.S. Food and Drug Administration is shown in Silver Spring near Washington

Varubi is given to patients in tablet form and it works best in combination with antiemetic agents, such as Granisetron and Dexamethasone.

“Chemotherapy-induced nausea and vomiting remains a major issue that can disrupt patients` lives and sometimes their therapy,” said Amy Egan, deputy director for safety in the FDA`s division of metabolism and endocrinology products. “Today’s approval provides cancer patients with another treatment option for the prevention of the delayed phase of nausea and vomiting caused by chemotherapy,” he added.

Delayed phase nausea and vomiting – occurring from 24 hours to up to 120 hours after the start of chemotherapy – can result in serious health problems. Prolonged nausea and vomiting usually leads to dehydration, weight loss, and malnutrition in cancerous patients, eventually leading to hospitalization.



Popular News

Latest News